FILE:HSP/HSP-8K-20090819140719.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
                                   
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
                                   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
                                   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
                                   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Item 8.01
                                            
Other Events
 
In a form 8-K filed on August 14, 2009, Hospira, Inc. ("Company") reported that, pursuant to legal proceedings not related to the safety of our product, the FDA suspended the ANDA approval for our oxaliplatin products.  On August 18, 2009, the court order initiating the ANDA suspension was dissolved.  On August 19, 2009, the Company received notice that the previously suspended ANDA has been reinstated by the FDA.  The Company has resumed shipments of the product.  Legal proceedings related to this product are ongoing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


